{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Rosiglitazone%29",
    "query": {
      "intervention": "Placebo (Rosiglitazone)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Rosiglitazone%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T12:57:45.363Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00413335",
      "title": "Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Impaired Glucose Tolerance",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-11",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413335"
    },
    {
      "nct_id": "NCT00337350",
      "title": "Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2003-09",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00337350"
    },
    {
      "nct_id": "NCT00274495",
      "title": "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone and Pegasys/Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-11-01",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274495"
    },
    {
      "nct_id": "NCT00015691",
      "title": "Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Lipodystrophy",
        "Hyperinsulinemia"
      ],
      "interventions": [
        {
          "name": "Metformin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 105,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Menlo Park",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015691"
    },
    {
      "nct_id": "NCT00428090",
      "title": "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 862,
      "start_date": "2007-02-27",
      "completion_date": "2008-09-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428090"
    },
    {
      "nct_id": "NCT00000620",
      "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis",
        "Cardiovascular Diseases",
        "Hypercholesterolemia",
        "Hypertension",
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus",
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Anti-hyperglycemic Agents",
          "type": "DRUG"
        },
        {
          "name": "Anti-hypertensive Agents",
          "type": "DRUG"
        },
        {
          "name": "Blinded fenofibrate or placebo plus simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 10251,
      "start_date": "1999-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 6,
      "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000620"
    },
    {
      "nct_id": "NCT00343395",
      "title": "Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "AVANDAMET",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intermountain Health Care, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2006-06",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-17",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "Murray, Utah",
      "locations": [
        {
          "city": "Murray",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343395"
    },
    {
      "nct_id": "NCT00130286",
      "title": "Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-Associated Lipodystrophy Syndrome",
        "Insulin Resistance",
        "HIV Infections",
        "Metabolic Syndrome X",
        "Body Weight Changes"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human growth hormone + rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "2005-03",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130286"
    },
    {
      "nct_id": "NCT00746174",
      "title": "Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insulin Sensitivity"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2004-02",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-09-03",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746174"
    },
    {
      "nct_id": "NCT00402909",
      "title": "Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Nateglinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-09-28T12:57:45.363Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402909"
    }
  ]
}